These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 16128602

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6months of therapy in cats using different IV infusion durations.
    Ruane T, Haskins M, Cheng A, Wang P, Aguirre G, Knox VW, Qi Y, Tompkins T, O'Neill CA.
    Mol Genet Metab; 2016 Feb; 117(2):157-63. PubMed ID: 26776148
    [Abstract] [Full Text] [Related]

  • 3. Laronidase.
    BioDrugs; 2002 Feb; 16(4):316-8. PubMed ID: 12196045
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis VI: clinical facts and figures.
    Harmatz P.
    Turk J Pediatr; 2010 Feb; 52(5):443-9. PubMed ID: 21434527
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study.
    Harmatz P, Giugliani R, Schwartz I, Guffon N, Teles EL, Miranda MC, Wraith JE, Beck M, Arash L, Scarpa M, Yu ZF, Wittes J, Berger KI, Newman MS, Lowe AM, Kakkis E, Swiedler SJ, MPS VI Phase 3 Study Group.
    J Pediatr; 2006 Apr; 148(4):533-539. PubMed ID: 16647419
    [Abstract] [Full Text] [Related]

  • 10. Enzyme replacement therapy with galsulfase for mucopolysaccharidosis type VI.
    Brunelli MJ, Atallah ÁN, da Silva EM.
    Cochrane Database Syst Rev; 2016 Mar 04; 3():CD009806. PubMed ID: 26943923
    [Abstract] [Full Text] [Related]

  • 11. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfatase.
    Harmatz P, Giugliani R, D Schwartz IV, Guffon N, Teles EL, Miranda MCS, Wraith JE, Beck M, Arash L, Scarpa M, Ketteridge D, Hopwood JJ, Plecko B, Steiner R, Whitley CB, Kaplan P, Yu ZF, Swiedler SJ, Decker C, MPS VI Study Group.
    Mol Genet Metab; 2008 Aug 04; 94(4):469-475. PubMed ID: 18502162
    [Abstract] [Full Text] [Related]

  • 12. The effect of galsulfase enzyme replacement therapy on the growth of patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
    Harmatz P, Hendriksz CJ, Lampe C, McGill JJ, Parini R, Leão-Teles E, Valayannopoulos V, Cole TJ, Matousek R, Graham S, Guffon N, Quartel A, MPS VI Study Group.
    Mol Genet Metab; 2017 Sep 04; 122(1-2):107-112. PubMed ID: 28457718
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Thrombocytopenia associated with galsulfase treatment.
    Doğan M, Cesur Y, Peker E, Oner AF, Dogan SZ.
    Hum Exp Toxicol; 2011 Jul 04; 30(7):768-71. PubMed ID: 20670992
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy for mucopolysaccharidosis VI: long-term cardiac effects of galsulfase (Naglazyme®) therapy.
    Braunlin E, Rosenfeld H, Kampmann C, Johnson J, Beck M, Giugliani R, Guffon N, Ketteridge D, Sá Miranda CM, Scarpa M, Schwartz IV, Leão Teles E, Wraith JE, Barrios P, Dias da Silva E, Kurio G, Richardson M, Gildengorin G, Hopwood JJ, Imperiale M, Schatz A, Decker C, Harmatz P, MPS VI Study Group.
    J Inherit Metab Dis; 2013 Mar 04; 36(2):385-94. PubMed ID: 22669363
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic profile of recombinant human N-acetylgalactosamine 4-sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): a phase I/II study.
    Harmatz P, Kramer WG, Hopwood JJ, Simon J, Butensky E, Swiedler SJ, Mucopolysaccharidosis VI Study Group.
    Acta Paediatr Suppl; 2005 Mar 04; 94(447):61-8; discussion 57. PubMed ID: 15895715
    [Abstract] [Full Text] [Related]

  • 19. Long-term galsulfase enzyme replacement therapy in Taiwanese mucopolysaccharidosis VI patients: A case series.
    Lin HY, Chuang CK, Wang CH, Chien YH, Wang YM, Tsai FJ, Chou YY, Lin SJ, Pan HP, Niu DM, Hwu WL, Ke YY, Lin SP.
    Mol Genet Metab Rep; 2016 Jun 04; 7():63-9. PubMed ID: 27134829
    [Abstract] [Full Text] [Related]

  • 20. A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase.
    El Dib RP, Pastores GM.
    Biologics; 2009 Jun 04; 3():459-68. PubMed ID: 19851471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.